ZBH Stock Analysis — Zimmer Biomet
Sector: Healthcare
AI Verdict
Zimmer Biomet trades at 11.6x next year's earnings with analysts projecting a 121.8% EPS jump—this is cheap for the growth on offer if their entrenched hospital relationships keep competitors at bay.
Competitive Moat
Zimmer Biomet specializes in orthopedic implants and surgical products, with a defensible position built on surgeon relationships, regulatory approvals, and a broad portfolio that makes hospital switching costly. Their established global distribution and clinical data create barriers for new entrants.
Summary
Zimmer Biomet is notable right now for a forecasted 121.8% jump in earnings, suggesting a sharp turnaround after a tough year.
Where It Stands
Zimmer Biomet is down -10.10% over the past year, trades at 11.6x next year's earnings versus the healthcare sector median of 22x, and its RSI of 49.5 signals neutral momentum.
Key Metrics
- RSI: 49.5 — Neutral
- Trailing P/E: 25.7x
- Forward P/E: 11.6x
- PEG Ratio: 0.21
- Earnings Growth: +1.2%
- Revenue Growth: +0.1%
- Market Cap: $17.7B
- Dividend Yield: 0.01%
- 1-Year Return: -10.10%
- 52-Week High: $108.29
- 52-Week Low: $84.59
Analyst Consensus
11 Buy · 20 Hold · 3 Sell (34 analysts)
Bull Case
With forward EPS expected to surge 121.8% and a forward P/E of just 11.6x, you're paying a low price for a major earnings rebound.
Bear Case
If the P/E reverts to the sector median of 22x after the rebound fails to materialize, the stock could see further downside from already negative 1-year returns.
Catalyst to Watch
Watch for quarterly earnings updates—confirmation of the forecasted EPS growth will determine if the valuation gap persists or closes.